Cargando…

Network Pharmacology-Based Study on the Molecular Biological Mechanism of Action for Qingdu Decoction against Chronic Liver Injury

BACKGROUND: Qingdu Decoction (QDD) is a traditional Chinese medicine formula for treating chronic liver injury (CLI). Materials and methods. A network pharmacology combining experimental validation was used to investigate potential mechanisms of QDD against CLI. We firstly screened the bioactive com...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Chongyang, Zhao, Mengpei, Du, Yuqiong, Jin, Shuang, Wu, Xiaoyi, Zou, Haiyan, Zhang, Qiuyun, Gao, Lianyin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952185/
https://www.ncbi.nlm.nih.gov/pubmed/33747110
http://dx.doi.org/10.1155/2021/6661667
_version_ 1783663671404134400
author Ma, Chongyang
Zhao, Mengpei
Du, Yuqiong
Jin, Shuang
Wu, Xiaoyi
Zou, Haiyan
Zhang, Qiuyun
Gao, Lianyin
author_facet Ma, Chongyang
Zhao, Mengpei
Du, Yuqiong
Jin, Shuang
Wu, Xiaoyi
Zou, Haiyan
Zhang, Qiuyun
Gao, Lianyin
author_sort Ma, Chongyang
collection PubMed
description BACKGROUND: Qingdu Decoction (QDD) is a traditional Chinese medicine formula for treating chronic liver injury (CLI). Materials and methods. A network pharmacology combining experimental validation was used to investigate potential mechanisms of QDD against CLI. We firstly screened the bioactive compounds with pharmacology analysis platform of the Chinese medicine system (TCMSP) and gathered the targets of QDD and CLI. Then, we constructed a compound-target network and a protein-protein interaction (PPI) network and enriched core targets in Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathways. At last, we used a CLI rat model to confirm the effect and mechanism of QDD against CLI. Enzyme-linked immunosorbent assay (ELISA), western blot (WB), and real-time quantitative polymerase chain reaction (RT-qPCR) were used. RESULTS: 48 bioactive compounds of QDD passed the virtual screening criteria, and 53 overlapping targets were identified as core targets of QDD against CLI. A compound-CLI related target network containing 94 nodes and 263 edges was constructed. KEGG enrichment of core targets contained some pathways related to CLI, such as hepatitis B, tumor necrosis factor (TNF) signaling pathway, apoptosis, hepatitis C, interleukin-17 (IL-17) signaling pathway, and hypoxia-inducible factor (HIF)-1 signaling pathway. Three PPI clusters were identified and enriched in hepatitis B and tumor necrosis factor (TNF) signaling pathway, apoptosis and hepatitis B pathway, and peroxisome pathway, respectively. Animal experiment indicated that QDD decreased serum concentrations of alanine aminotransferase (ALT), aspartate aminotransferase (AST), endotoxin (ET), and IL-17 and increased prothrombin time activity (PTA) level. WB and RT-qPCR analyses indicated that, compared with the model group, the expression of cysteinyl aspartate specific proteinase-9 (caspase-9) protein, caspase-3 protein, B-cell lymphoma-2 associated X protein (Bax) mRNA, and cytochrome c (Cyt c) mRNA was inhibited and the expression of B-cell lymphoma-2 (Bcl-2) mRNA was enhanced in the QDD group. CONCLUSIONS: QDD has protective effect against CLI, which may be related to the regulation of hepatocyte apoptosis. This study provides novel insights into exploring potential biological basis and mechanisms of clinically effective formula systematically.
format Online
Article
Text
id pubmed-7952185
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-79521852021-03-19 Network Pharmacology-Based Study on the Molecular Biological Mechanism of Action for Qingdu Decoction against Chronic Liver Injury Ma, Chongyang Zhao, Mengpei Du, Yuqiong Jin, Shuang Wu, Xiaoyi Zou, Haiyan Zhang, Qiuyun Gao, Lianyin Evid Based Complement Alternat Med Research Article BACKGROUND: Qingdu Decoction (QDD) is a traditional Chinese medicine formula for treating chronic liver injury (CLI). Materials and methods. A network pharmacology combining experimental validation was used to investigate potential mechanisms of QDD against CLI. We firstly screened the bioactive compounds with pharmacology analysis platform of the Chinese medicine system (TCMSP) and gathered the targets of QDD and CLI. Then, we constructed a compound-target network and a protein-protein interaction (PPI) network and enriched core targets in Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathways. At last, we used a CLI rat model to confirm the effect and mechanism of QDD against CLI. Enzyme-linked immunosorbent assay (ELISA), western blot (WB), and real-time quantitative polymerase chain reaction (RT-qPCR) were used. RESULTS: 48 bioactive compounds of QDD passed the virtual screening criteria, and 53 overlapping targets were identified as core targets of QDD against CLI. A compound-CLI related target network containing 94 nodes and 263 edges was constructed. KEGG enrichment of core targets contained some pathways related to CLI, such as hepatitis B, tumor necrosis factor (TNF) signaling pathway, apoptosis, hepatitis C, interleukin-17 (IL-17) signaling pathway, and hypoxia-inducible factor (HIF)-1 signaling pathway. Three PPI clusters were identified and enriched in hepatitis B and tumor necrosis factor (TNF) signaling pathway, apoptosis and hepatitis B pathway, and peroxisome pathway, respectively. Animal experiment indicated that QDD decreased serum concentrations of alanine aminotransferase (ALT), aspartate aminotransferase (AST), endotoxin (ET), and IL-17 and increased prothrombin time activity (PTA) level. WB and RT-qPCR analyses indicated that, compared with the model group, the expression of cysteinyl aspartate specific proteinase-9 (caspase-9) protein, caspase-3 protein, B-cell lymphoma-2 associated X protein (Bax) mRNA, and cytochrome c (Cyt c) mRNA was inhibited and the expression of B-cell lymphoma-2 (Bcl-2) mRNA was enhanced in the QDD group. CONCLUSIONS: QDD has protective effect against CLI, which may be related to the regulation of hepatocyte apoptosis. This study provides novel insights into exploring potential biological basis and mechanisms of clinically effective formula systematically. Hindawi 2021-03-03 /pmc/articles/PMC7952185/ /pubmed/33747110 http://dx.doi.org/10.1155/2021/6661667 Text en Copyright © 2021 Chongyang Ma et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ma, Chongyang
Zhao, Mengpei
Du, Yuqiong
Jin, Shuang
Wu, Xiaoyi
Zou, Haiyan
Zhang, Qiuyun
Gao, Lianyin
Network Pharmacology-Based Study on the Molecular Biological Mechanism of Action for Qingdu Decoction against Chronic Liver Injury
title Network Pharmacology-Based Study on the Molecular Biological Mechanism of Action for Qingdu Decoction against Chronic Liver Injury
title_full Network Pharmacology-Based Study on the Molecular Biological Mechanism of Action for Qingdu Decoction against Chronic Liver Injury
title_fullStr Network Pharmacology-Based Study on the Molecular Biological Mechanism of Action for Qingdu Decoction against Chronic Liver Injury
title_full_unstemmed Network Pharmacology-Based Study on the Molecular Biological Mechanism of Action for Qingdu Decoction against Chronic Liver Injury
title_short Network Pharmacology-Based Study on the Molecular Biological Mechanism of Action for Qingdu Decoction against Chronic Liver Injury
title_sort network pharmacology-based study on the molecular biological mechanism of action for qingdu decoction against chronic liver injury
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952185/
https://www.ncbi.nlm.nih.gov/pubmed/33747110
http://dx.doi.org/10.1155/2021/6661667
work_keys_str_mv AT machongyang networkpharmacologybasedstudyonthemolecularbiologicalmechanismofactionforqingdudecoctionagainstchronicliverinjury
AT zhaomengpei networkpharmacologybasedstudyonthemolecularbiologicalmechanismofactionforqingdudecoctionagainstchronicliverinjury
AT duyuqiong networkpharmacologybasedstudyonthemolecularbiologicalmechanismofactionforqingdudecoctionagainstchronicliverinjury
AT jinshuang networkpharmacologybasedstudyonthemolecularbiologicalmechanismofactionforqingdudecoctionagainstchronicliverinjury
AT wuxiaoyi networkpharmacologybasedstudyonthemolecularbiologicalmechanismofactionforqingdudecoctionagainstchronicliverinjury
AT zouhaiyan networkpharmacologybasedstudyonthemolecularbiologicalmechanismofactionforqingdudecoctionagainstchronicliverinjury
AT zhangqiuyun networkpharmacologybasedstudyonthemolecularbiologicalmechanismofactionforqingdudecoctionagainstchronicliverinjury
AT gaolianyin networkpharmacologybasedstudyonthemolecularbiologicalmechanismofactionforqingdudecoctionagainstchronicliverinjury